Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two agents with distinct pharmacological actions: - **Thrombin** is a serine protease enzyme that plays a central role in the coagulation cascade. It converts fibrinogen to fibrin, leading to clot formation. Thrombin is used topically as a hemostatic agent to control bleeding during surgical procedures or from minor wounds[8]. - **L-dopa (levodopa)** is an amino acid precursor of dopamine. It crosses the blood-brain barrier and is converted into dopamine in the brain, supplementing deficient levels seen in Parkinson's disease and related disorders. L-dopa is primarily used for symptomatic treatment of Parkinson's disease[2][5]. There are no known approved pharmaceutical products or clinical evidence supporting the use of this specific combination (thrombin + L-dopa) as a single drug entity for any indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thrombin + L-dopa.